MedTrace Logo

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

NCT05904028 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2026-05-18

No results posted yet for this study

Summary

Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule

Intravitreal injections of 6 mg faricimab on a Treat and Extend schedule

DEVICE

Intravitreal injections of 6 mg faricimab on a home optical coherence tomography-guided treatment schedule

Intravitreal injections of 6 mg faricimab on a Home OCT-guided treatment schedule

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Eye Institute (NEI)

    collaborator NIH

  • Juvenile Diabetes Research Foundation

    collaborator OTHER

  • Jaeb Center for Health Research

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-09
Primary Completion
2027-07-30
Completion
2027-07-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05904028 on ClinicalTrials.gov